Abstract:BackgroundAlzheimer’s disease (AD) biomarker tests can be ordered as part of the diagnostic workup of patients with mild cognitive impairment (MCI). Little is known about how patients with MCI and their care partners decide whether to pursue testing.ObjectiveTo examine factors that influence AD biomarker testing decisions among patients with MCI and their care partners.DesignWe performed structured research interviews with patients with MCI and their study partners to assess the importance of eight factors in the decision whether to undergo AD biomarker testing (6-point Likert scale; 1-extremely unimportant to 6-extremely important): cost, fear of testing procedures, learning if AD is the cause of cognitive problems, concern about health insurance, instructing future planning, informing treatment decisions, family members’ opinions, and doctor recommendation.SettingTwo researchers administered interviews with participants in-person (i.e., participant home, research center) or remotely (i.e., telephone, video-conference).ParticipantsWe completed interviews with 65 patients with a diagnosis of MCI and 57 study partners, referred by dementia specialist clinicians from the University of California, Irvine health system.MeasurementsWe used generalized estimating equations (GEE) to examine the mean importance of each factor among patients and study partners, and the mean difference in importance of each factor within dyads.ResultsOne third of participants reported the patient had previously undergone AD biomarker testing. Fifty-five percent of patients and 65% of study partners who reported no previous testing indicated a desire for the patient to be tested. GEE analyses found that patients and study partners rated the following factors with highest importance: informing treatment decisions (mean score 5.29, 95% CI: 5.06, 5.52 for patients; mean score 5.56, 95% CI: 5.41, 5.72 for partners); doctor recommendation (4.94, 95% CI: 4.73, 5.15 for patients; 5.16, 95% CI: 4.97, 5.34 for partners); and instructing future planning (4.88, 95% CI: 4.59, 5.16 for patients; 5.11, 95% CI: 4.86, 5.35 for partners). High dyadic agreement was observed for all factors except fear of testing, which patients rated with lower importance than their study partners.ConclusionsBiomarker testing for AD in patients with MCI is a rapidly evolving practice and limited data exist on patient perspectives. In this study, most patients and their care partners were interested in testing to help inform treatment decisions and to plan for the future. Participants placed high importance on clinician recommendations for biomarker testing, highlighting the need for clear communication and education on the options, limitations, risks, and benefits of testing.

Why to test for dementia: perspectives of patients, significant others and general practitioners

Doing the Right Thing? General Practitioners' Considerations in Achieving a Timely Dementia Diagnosis

Exploring diagnostic strategies for memory complaints in older adults: A retrospective general practice database study

Documentation of shared decision-making in diagnostic testing for dementia in Dutch general practice: A retrospective study in electronic patient records

The expectations and experiences of patients regarding the diagnostic workup at a specialized memory clinic: An interview study

Patients' and carers' views on communication and information provision when undergoing assessments in memory services

Alzheimer’s Disease Biomarker Decision-Making among Patients with Mild Cognitive Impairment and Their Care Partners

Australian medical practitioners' perspectives about current practice relating to fitness to drive assessment for older people with dementia and mild cognitive impairment: A qualitative study

Diagnostic information in GP referral letters to a memory clinic: a cohort study

Dementia Specialty Care Clinicians' Perspectives on Their Role in the Dementia Diagnostic Process and Diagnostic Disclosure

Computerized decision support to optimally funnel patients through the diagnostic pathway for dementia

Best Practices for Communicating a Diagnosis of Dementia: Results of a Multi-Stakeholder Modified Delphi Consensus Process

Decision making under uncertainty in the diagnosis and management of Alzheimer's Disease in primary care: A study protocol applying concepts from neuroeconomics

People's interest in brain health testing: Findings from an international, online cross-sectional survey

The Association of Ancillary Diagnostic Tests With Outcome in Dementia

[Limited cognitive assessment in primary care: are GP referrals to the memory clinic always appropriate?]

Dissonance in the face of Alzheimer's disease breakthroughs: clinician and lay stakeholder acceptance, concerns and willingness to pay for emerging disease-modifying therapies

'It is empowering and gives people dignity in a very difficult process': A multistage, multimethod qualitative study to understand the views of end users in the cultural adaptation of a dementia and driving decision aid

Supportive care decision-making processes of persons with dementia and their caregivers

Assessing cognitive function in longitudinal studies of ageing worldwide: some practical considerations

What influences decisions about ongoing stroke rehabilitation for patients with pre-existing dementia or cognitive impairment: a qualitative study?